Brexpiprazole

Brexpiprazole (brand name Rexulti) is an atypical antipsychotic medication approved for the treatment of schizophrenia and as an adjunctive therapy in major depressive disorder. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors.

It is prescribed primarily to improve symptoms such as hallucinations, delusions, and mood disturbances by modulating neurotransmitter activity in the central nervous system.

The drug is a partial agonist at D2 and 5-HT1A and an antagonist at 5-HT2A. The mixed activity is the basis for its effect on mood and psychotic symptoms; it's also why brexpiprazole behaves differently from older antipsychotics that simply block dopamine.

The primary gene influencing brexpiprazole metabolism is CYP2D6. CYP2D6 is a liver enzyme in the cytochrome P450 family responsible for converting brexpiprazole into inactive metabolites through oxidative processes. Variations in the CYP2D6 gene can alter enzyme activity, affecting how quickly the drug is cleared from the body.

Individuals with certain CYP2D6 variants may process brexpiprazole at different rates: those with reduced-function alleles may clear the drug more slowly, leading to higher systemic concentrations, while those with increased-function alleles may eliminate the drug more rapidly, potentially reducing efficacy.

Depending on the CYP2D6 metabolizer phenotype—ultrarapid, normal, intermediate, poor, or indeterminate—the plasma concentration of brexpiprazole can vary significantly. Poor metabolizers tend to have higher drug levels, increasing the risk of side effects, whereas ultrarapid metabolizers may have lower exposure and a potential loss of efficacy. Normal and intermediate metabolizers usually follow standard dosing, and indeterminate metabolizer status warrants standard dosing with careful monitoring.

Ultrarapid Metabolizer

• Effect: Increased metabolism leading to lower brexpiprazole levels
• Clinical consequence: Potential reduced therapeutic efficacy
• Side effects: Typically minimal; risk of subtherapeutic response (infrequent)

Normal Metabolizer

• Effect: Standard metabolism and drug exposure
• Clinical consequence: Expected typical clinical response
• Side effects: Standard risk profile (common mild side effects like weight gain, akathisia)

Intermediate Metabolizer

• Effect: Moderately slower metabolism with slightly higher drug levels
• Clinical consequence: Generally effective response; monitor for increased side effects
• Side effects: Mild to moderate side effects (possible sedation, dizziness)

Poor Metabolizer

• Effect: Markedly reduced metabolism resulting in higher brexpiprazole concentrations
• Clinical consequence: Increased risk of dose-related adverse effects
• Side effects: Moderate to severe side effects (e.g., sedation, extrapyramidal symptoms; frequency variable)

Indeterminate/Not available

• Effect: Unknown
• Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring
• Side effects: Cannot be predicted; monitor patient response closely

CYP2D6 Dosing Guideline

No alternative treatments are specified in the FDA pharmacogenetic guidance for brexpiprazole. Clinicians may consider other atypical antipsychotics such as aripiprazole or risperidone based on patient response and tolerability.

• FDA – Table of Pharmacogenetic Associations